Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination Study

Goal

The ultimate aim of the study is to enhance the Canadian public’s confidence in vaccine safety.

Study Description

The Canadian Cardiovascular Society (CCS) National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre study funded by the Public Health Agency of Canada. MYCOVACC is assessing the outcomes of adult and pediatric patients with myocarditis and/or pericarditis following mRNA vaccination for up to three years.

CEBI’s Role

CEBI developed guides for health care provider and patient stakeholder consultations, reviewed evidence updates, drafted an evidence-based care management algorithm for providers, and created a patient information sheet. The current evidence update, care algorithm and patient information sheet are now available on the CCS website: MYCOVACC – Canadian Cardiovascular Society (ccs.ca).

For more information about this work, please contact CEBI by email at cebi@hhsc.ca.